Loeb's Third Point Accumulates $174.8M Chipotle Position Amid Valuation Pressures

BenzingaBenzinga
|||1 min read
Key Takeaway

Activist investor Dan Loeb's Third Point builds $174.8M Chipotle stake as stock faces valuation pressures from weak 2026 guidance and 28% decline.

Loeb's Third Point Accumulates $174.8M Chipotle Position Amid Valuation Pressures

Activist investor Dan Loeb's Third Point LLC established a significant 4.75 million share position in Chipotle Mexican Grill during the fourth quarter of 2025, representing a $174.8 million investment. The stake accumulation comes as the fast-casual restaurant operator faces investor skepticism following conservative guidance for 2026, during which the company projects comparable sales growth to remain essentially flat.

Chipotle's fourth-quarter results exceeded revenue expectations, yet the muted outlook prompted multiple equity analysts to reduce price targets on the stock. The disappointing guidance has weighed heavily on investor sentiment, with the shares declining 28.96% over the trailing twelve-month period and currently trading near their 52-week lows.

The positioning diverges from broader quick-service restaurant performance, as Chipotle has significantly underperformed major sector peers including McDonald's and Starbucks over the same timeframe. Third Point's investment suggests conviction that current valuations may not fully reflect the company's long-term potential, though the rationale for the activist stake remains subject to future strategic communications from the fund.

Source: Benzinga

Back to newsPublished Feb 24

Related Coverage

The Motley Fool

Icahn Doubles Down on Centuri with $78M Stock Purchase, Signaling Long-Term Conviction

Icahn Enterprises added $78M in Centuri shares in Q4 2025, expanding stake to 14.3M shares worth $362M, following earlier private placement investment.

CTRIIEP
GlobeNewswire Inc.

Corcept Therapeutics Faces Class Action Over FDA Rejection; Stock Crashed 50%

Corcept Therapeutics faces securities fraud lawsuit after FDA rejected relacorilant application. Stock plummeted 50.4% following December rejection. Investor deadline April 21, 2026.

CORT
Investing.com

D-Wave's 44% Plunge Masks Quantum Leap: Growth Story vs. Valuation Reality

D-Wave ($QBTS) fell 44% in 2026 despite strong bookings exceeding 2025 totals and $30M in major deals. Analysts see 132% upside, but 237x sales valuation remains extreme.

QBTS
GlobeNewswire Inc.

OneMain Holdings Faces Multi-State Securities Probe Over Alleged Lending Fraud

Pomerantz Law Firm investigates $OMF following multi-state lawsuit alleging deceptive lending practices. Stock tumbles 5.38% on fraud allegations.

OMF
Investing.com

Chipotle's Menu Comeback Sparks Analyst Upgrades as Turnaround Gains Momentum

Chipotle rebounds with Chicken al Pastor relaunch boosting Q1 traffic. Multiple analyst upgrades target 50% upside; activist Dan Loeb's Third Point takes position.

CMG
GlobeNewswire Inc.

Boston Scientific Faces Securities Fraud Lawsuit Over Overstated EP Growth Claims

Boston Scientific faces class action lawsuit alleging material misstatements about electrophysiology growth. Stock fell 17.6% after disclosing slower market growth and competitive pressures.

BSX